Moderna, Inc. $MRNA Stock Holdings Reduced by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH cut its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 41.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,899 shares of the company’s stock after selling 57,182 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Moderna were worth $2,064,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in MRNA. Norges Bank acquired a new position in Moderna in the second quarter worth approximately $94,910,000. Federated Hermes Inc. grew its position in Moderna by 364.5% in the second quarter. Federated Hermes Inc. now owns 2,869,271 shares of the company’s stock worth $79,163,000 after acquiring an additional 2,251,497 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Moderna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock worth $244,458,000 after purchasing an additional 1,420,690 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Moderna by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock valued at $1,150,743,000 after purchasing an additional 1,312,192 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Moderna by 20.7% during the 2nd quarter. Invesco Ltd. now owns 7,101,032 shares of the company’s stock valued at $195,917,000 after purchasing an additional 1,217,408 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Up 3.4%

MRNA opened at $46.86 on Friday. The stock’s 50 day moving average price is $33.55 and its two-hundred day moving average price is $29.18. The firm has a market capitalization of $18.31 billion, a P/E ratio of -5.81 and a beta of 1.17. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $55.20.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $1.64. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.Moderna’s revenue for the quarter was down 45.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.03 earnings per share. As a group, analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Moderna from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. Bank of America lowered their price objective on Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, November 10th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Moderna in a research note on Monday, January 12th. JPMorgan Chase & Co. decreased their target price on Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a research report on Thursday, October 23rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $28.77.

Insider Activity

In other news, Director Noubar Afeyan sold 23,853 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.90% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.